Stay updated on Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Sign up to get notified when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    A New York site was added under Locations, replacing the previous New York Locations entry. The HHS Vulnerability Disclosure link was removed from the footer, and the page shows Revision: v3.3.3.
    Difference
    0.2%
    Check dated 2025-12-23T20:34:55.000Z thumbnail image
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    No Change Detected
  5. Check
    41 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.2; no changes to core study details or user-facing information are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T14:15:41.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Deleted the funding-lapse warning block that warned users information may not be up to date due to government funding gaps; core study details remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-18T07:30:25.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The two screenshots show only minor layout adjustments and wording changes on the study page, with no edits to core study data such as eligibility criteria, endpoints, locations, or protocol. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-10-27T21:08:11.000Z thumbnail image
  8. Check
    91 days ago
    Change Detected
    Summary
    Summary of changes: added a government-operating-status notice and new version v3.2.0; removed the older disease entry (B-cell chronic lymphocytic leukemia) and old version v3.1.0.
    Difference
    3%
    Check dated 2025-10-06T08:24:44.000Z thumbnail image
  9. Check
    98 days ago
    Change Detected
    Summary
    Version updated from v3.0.2 to v3.1.0; no other content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T05:09:34.000Z thumbnail image

Stay in the know with updates to Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Ibrutinib and Pembrolizumab in CLL/MCL Clinical Trial page.